MagForce AG : MagForce AG Publishes First Quarterly Shareholder Letter
MagForce AG / MagForce AG Publishes First Quarterly Shareholder Letter . Ad
hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this
Berlin, Germany, July 24, 2013 - MagForce AG (Frankfurt, Xetra: MF6), a
leading medical device company in the area of nanotechnology with a focus on
oncology, published today its first "Shareholder Letter".
Subsequently, such shareholder letters shall be published quarterly in order
to keep shareholders well informed about the ongoing developments and
The shareholder letter can be downloaded here:
Key points are
*Personal introduction of Dr. Ben Lipps, designated CEO and Chairman of the
*Focus on recurrent Glioblastoma Multiform Cancer (GBM) and Prostate Cancer
*Details to GBM post-marketing study
*Search for strategic partners in Emerging Markets.
About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine
in oncology, listed in the entry standard (MF6). The Company's proprietary,
NanoTherm^® therapy, enables the targeted treatment of solid tumors through
the intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm^®, NanoPlan^®, and NanoActivator(TM) are components
of the therapy and have received EU-wide regulatory approval as medical
devices for the treatment of brain tumors. MagForce, NanoTherm^®, NanoPlan^®,
and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For
more information, please visit www.magforce.com.
Full Resume Dr. Ben Lipps
Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management
Board of Fresenius Medical Care in May 1999. In December 2012 he stepped down
as Chairman of the Management Board and CEO. During his term, Fresenius
Medical Care's sales tripled from 3.8 to 12.8 billion dollars, and the annual
net profit grew 6 times to 1.1 billion dollars.
He was also Chief Executive Officer of Fresenius Medical Care North America
until February 2004. He was President, Chief Executive Officer, Chief
Operating Officer and a director of Fresenius USA from October 1989 through
February 2004, and served in various capacities with Fresenius USA's
predecessor from 1985 through 1989.
He earned his master's and doctoral degrees at the Massachusetts Institute of
Technology in chemical engineering. Before joining the Fresenius Group in
1985, Dr. Lipps held several research management positions in various
companies, among them with DOW Chemical.
This release may contain forward-looking statements and information which may
be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will".
Such forward-looking statements are based on our current expectations and
certain assumptions, which may be subject to a variety of risks and
uncertainties. The results actually achieved by MagForce AG may substantially
differ from these forward-looking statements. MagForce AG assumes no
obligation to update these forward-looking statements or to correct them in
case of developments, which differ from those, anticipated.
MC Services AG
T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759
MagForce_Press Release_July 24, 2013
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: MagForce AG via Thomson Reuters ONE
--- End of Message ---
Max-Dohrn-Str. 8 Berlin Germany
WKN: A0HGQF;ISIN: DE000A0HGQF5;
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.